Search

Your search keyword '"Schönland, Stefan"' showing total 944 results

Search Constraints

Start Over You searched for: Author "Schönland, Stefan" Remove constraint Author: "Schönland, Stefan" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
944 results on '"Schönland, Stefan"'

Search Results

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

3. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

4. Systemic Light Chain Amyloidosis

5. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

6. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

8. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

9. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

12. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

13. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

14. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

15. Amyloidose

16. Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial

17. Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens

18. Proposed hematologic progression criterion in patients with AL amyloidosis.

24. Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study

25. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network

29. Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

30. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

31. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

32. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

36. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.

38. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

39. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

40. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

41. Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information

43. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

44. Search for AL amyloidosis risk factors using Mendelian randomization

46. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

49. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

50. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.

Catalog

Books, media, physical & digital resources